ZBH250117C140000
- 0.27
- 0.000.00%
Zimmer Biomet Holdings Newsroom
Zimmer Biomet Holdings (ZBH) Gets a Hold From Wells Fargo
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $130
Zimmer Biomet Holdings Analyst Ratings
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $118
Bernstein Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $133
J.P. Morgan Upgrades Zimmer Biomet Holdings(ZBH.US) to Buy Rating, Raises Target Price to $128
Zimmer Biomet Holdings Analyst Ratings
Barclays Cuts Zimmer Biomet Price Target to $118 From $125, Maintains Underweight Rating
Citi Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $120
Morgan Stanley Initiates Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $115
Wells Fargo Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Hold Rating for Zimmer Biomet Holdings Amid Uncertain Impact of New Product Launch in US Market
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Zimmer Biomet Holdings Is Maintained at Outperform by RBC Capital
Zimmer Biomet Holdings Analyst Ratings
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $125
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $117
Truist Securities Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $117